Format

Send to

Choose Destination
Pharmacogenomics. 2015;16(7):673-6. doi: 10.2217/pgs.15.32. Epub 2015 May 1.

Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014).

Author information

1
2IPN-CIIDIR, Unidad Durango, Durango, Mexico.
2
3Universidad Católica Argentina, Buenos Aires, Argentina.
3
5UNAN-León, Universidad Nacional Autónoma de Nicaragua, León, Nicaragua.
4
6USFQ, Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Quito, Ecuador.
5
7UFMG, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
6
8UCR, Universidad de Costa Rica, San José, Costa Rica.
7
9UP, Universidad de Panama, Panama.

Abstract

MESTIFAR 2014 28-30 November 2014, Panama City, Panama The CEIBA consortium was created within the Ibero-American network of Pharmacogenetics (RIBEF) to study population pharmacogenetics. The current status of these initiatives and results of the MESTIFAR project were analyzed in Panama, 28-30 November 2014. The MESTIFAR project focused on studying CYPs genetic polymorphisms in populations of different ethnic origin. So far, more than 6000 healthy volunteers have been evaluated, making this one of the largest population pharmacogenomic studies worldwide. Three symposia were organized, 'Pharmacogenetics of indigenous and mestizos populations and its clinical implications', 'Methodological innovation in pharmacogenetics and its application in health', and 'General discussion and concluding remarks', about mechanisms and proposals for training, diffusion of pharmacogenetics for Spanish- and Portuguese-speaking health professionals, and 'bench to bedside' pilot projects.

KEYWORDS:

Ibero-Americans populations; cytochrome P450; drug metabolism; genome-wide analyses; metabolic phenotypes; next-generation sequencing; pharmacogenetics; population genetics

PMID:
25929854
DOI:
10.2217/pgs.15.32
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center